patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Hub Home

> Log In

Demo Video
Private Messages
Edit My Profile
View/Edit Portfolio

AGORACOM News Flash

AGORACOM WIRE - FRIDAY MAY 25TH, 2012

FOCUS METALS (TSXV:FMS) Changes Its Name to Focus Graphite Inc.

Aim to develop and manufacture the best technology graphite in the world
Additional shareholder value will come from investment in commercialized graphene through joint venture partner, Grafoid Inc.

Read More | *SPONSOR

INTERNATIONAL PBX VENTURES (TSX:PBX) Signs Copaquire Joint Venture Option Agreement - $90M Potential Payment Read More

AGORACOM Maintenance Alert: Friday Evening Downtime for About an Hour Read More

LOMIKO METALS (TSXV:LMR) Graphite and Zinc Price Outlook is Favourable Through 2013 Read More | *SPONSOR

Message: Pluristem Therapeutics to Present at Leading U.S. Industry Conferences

Reply New Message

« Prev Message Back To Forum Go to Threaded View Next Message »

emit

Rank: [?]

Vice President

Points: [?]

21380

Rating: [?]

Votes: 166 Score: 3.0

Currently 3.1/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Pluristem Therapeutics to Present at Leading U.S. Industry Conferences

posted on Sep 06, 11 04:16PM (Log in to use the IP Check tool) ^[?]

Pluristem Therapeutics to Present at Leading U.S. Industry Conferences

HAIFA, Israel, Sept. 6, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI - News) (TASE:PLTR) announced today that Company executives will be presenting at five leading scientific and financial events in the U.S. during the month of September. The presentations will focus on Pluristem's work towards the potential development of placenta-derived stem cell treatments for a variety of illnesses as well as on the company's strategy.

During the month of September, Pluristem will be presenting at the following conferences:

35th Annual Meeting of the AATB - September 8-12, Scottsdale, Arizona.
Dr. William R. Prather, Sr. VP Corporate Development, will present: "The use of Placenta-derived MSCs in the treatment of radiation exposure" on Sunday, September 11, 2011 from 3:15 to 4:15 PM
Rodman & Renshaw Conference - September 11-13, New York, New York.
Yaky Yanay, VP Finance and CFO, will present: "Cell Therapy and Its Future Role in Reducing Healthcare Spending" on Tuesday, September 13, 2:00-2:25 PM, Sutton Suite
UBS Global Life Sciences Conference - September 19-21, New York, New York.
Zami Aberman, Chairman and CEO, will present the Company on Tuesday, September 20, 2011 at 4:00 PM
The Cell Therapy Commercialization Summit - September 19-21, 2011, Boston, Massachusetts.
Dr. William R. Prather, Sr. VP of Corporate Development, will present the Company on Monday, September 19, 2011, 9:00-9:30 AM
8th Annual Israel Strategic Partner and Venture Conference-Life Sciences and Medical Devices - September 22, 2011, Princeton, New Jersey.
Dr. William R. Prather, Sr. VP of Corporate Development, will present the Company
European Society of Cardiology: International Conference on Heart Failure with Preserved Ejection Fraction: Basic mechanisms - September 23-25, Budapest, Hungary.
Frida Grynspan, PhD, VP of Research and Development, will present: "HFPEF and stem cells" Session VII -- Therapy, on Sunday, September 25, 2011 10:20-10:40 AM.

Reply New Message

« Prev Message Back To Forum Go to Threaded View Next Message »

New Message

Please login to post a reply

Agoracom TV

Check out Agoracom's daily, fast-paced, newscast on the morning's top Small-Cap newsmakers

Mesh With Us On The Web's Top Social Networking Sites

Find Our Content Throughout The Web With Our New Media Partners

AGORACOM Quick Tips

Start A New HUB. Control. Quality. Refreshing. ... Start One Now

Click To Watch Today's Show

President's D.D.

5-9-12, Pluristem's PLX Cells Saves the Life of a Child after Bone Marrow Transplantation Failure.

4-17-12, Pluristem Receives U.S. FDA Clearance for Phase II Clinical Trial for the treatment of peripheral artery disease (PAD). read more

Stock Quote

Open PSTI Stock Quote

Investment Ideas

Like Pluristem Life Systems, Inc.? Then you might also be interested in Star Navigation Systems Group Ltd.

Star Navigation Systems Group Ltd.

Developer of the TERRASTARTM in-flight safety monitoring system
The first system in the world to feature real-time in-flight data monitoring and diagnostics
echnical Partnership Agreement with Astrium, a wholly owned subsidiary of EADS